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CTLA-4 Regulates Induction of Anergy In Vivo
cules is more than one of costimulation, since B7:CTLA-4Rebecca J. Greenwald,* Vassiliki A. Boussiotis,†
interactions deliver inhibitory signals that terminate TRobert B. Lorsbach,‡ Abul K. Abbas,§
cell responses. The affinity of CTLA-4 for B7 ligands inand Arlene H. Sharpe*k
vitro is 20- to 50-fold higher than CD28 (Linsley et al.,* Immunology Research Division
1994). The distinct avidities of the B7 ligands for CD28Department of Pathology
and CTLA-4, together with their highly regulated expres-Brigham and Women’s Hospital
sion, have led to a model in which B7:CD28 or B7:Harvard Medical School
CTLA-4 interactions predominate at distinct stages of†Department of Adult Oncology
an immune response. When B7 ligands are expressedDana-Farber Cancer Institute
at low levels, the B7 costimulators may preferentiallyBoston, Massachusetts 02115
engage the high-affinity inhibitory receptor CTLA-4.‡St. Jude’s Children’s Research Hospital
When the B7 ligands are upregulated and expressed atMemphis, Tennessee 38105
high levels, such as upon encounter with immunogenic§Department of Pathology
antigens or adjuvants, the predominant interactions mayUniversity of California, San Francisco
be between CD28 and B7, enhancing T cell proliferationSan Francisco, California 94143
and differentiation. As CTLA-4 expression becomes
upregulated following T cell activation, the inhibitory
B7:CTLA-4 interaction would once again predominate,Summary
and T cell activation would be terminated. As B7 expres-
sion declines to low levels, all the available B7 may beThe requirement for CTLA-4 during the induction of
engaged by high-affinity CTLA-4, again favoring down-peripheral T cell tolerance in vivo was investigated
regulation of the T cell response.using naive TCR transgenic T cells lacking CTLA-4.
CTLA-4 expression on naive and effector T cells mayCTLA-42/2 T cells are resistant to tolerance induction,
influence T cell responses to immunogenic and tolero-as demonstrated by their proliferative responses, IL-2
genic stimuli. In contrast to constitutive cell surface ex-production, and progression into the cell cycle. Fol-
pression of CD28, CTLA-4 is difficult to detect on thelowing exposure to a tolerogenic stimulus in vivo and
surface of T cells because it is predominately intracellu-restimulation in vitro, wild-type T cells are blocked at
lar. (Linsley et al., 1990; June et al., 1994; Scheipers andthe late G1 to S restriction point of the cell cycle. In
Reiser, 1998b). Cell surface expression of CTLA-4 iscontrast, CTLA-42/2 T cells enter into the S phase of
tightly regulated and peaks at 48 hr (Alegre et al., 1996;the cell cycle, as shown by downregulation of p27kip1,
Zhang and Allison, 1997). Despite the difficulty in de-elevated cdk2 kinase activity, and Rb hyperphosphory-
tecting CTLA-4 expression on naive T cells, there islation. Thus, CTLA-4 has an essential role in determin-
some evidence that CTLA-4 may be functionally impor-ing the outcome of T cell encounter with a tolerogenic
tant on naive T cells (Brunner et al., 1999). Thus, CTLA-4stimulus.
may provide key regulatory signals at the initiation as
well as the effector phase of the immune response.Introduction
There are reports to suggest that T cells transit
through an aborted activation state prior to becomingElucidating the signals that influence the choice be-
tolerized (Vidard et al., 1994, 1995; Chai and Lechler,tween T cell activation and tolerance is likely to provide
1997). Whether costimulatory molecules are needed for
important insights into the regulation of physiologic im-
this activation and thereby have a role during tolerance
munity, as well as pathologic states, such as autoimmu-
induction has not been well-defined in vivo. In several
nity, that result from the failure of self-tolerance. The models, administration of anti-CTLA-4 antibodies to
fatal lymphoproliferative disease that develops in CTLA- mice given a tolerogenic stimulus prevented the induc-
4-deficient (2/2) mice provided direct evidence for a tion of tolerance and resulted in the development of
critical role for CTLA-4 in downregulating T cell activa- antigen-reactive T cells (Perez et al., 1997; Walunas and
tion (Tivol et al., 1995; Waterhouse et al., 1995). This Bluestone, 1998). Potential explanations for these re-
phenotype also suggested that B7:CTLA-4 interactions sults include (1) anti-CTLA-4 mAbs blocked B7:CTLA-4
may be required for maintaining peripheral T cell toler- interactions required for tolerance induction, (2) anti-
ance and prompted studies investigating this issue. CTLA-4 mAbs prevented T cells from producing regula-
Interactions in the B7:CD28/CTLA-4 pathway are tory cytokines such as IL-10 or TGF-b, and/or (3) anti-
complex, since B7-1 and B7-2 have dual specificities CTLA-4 mAbs provided partial antagonistic effects on
for the CD28 and CTLA-4 receptors on T cells (Linsley CTLA-4 in vivo due to inadequate penetration or incom-
et al., 1990; Azuma et al., 1993; Freeman et al., 1993). plete blockade, resulting in cytokine production by non-
B7-1 and B7-2 provide the major costimulatory signal inhibited T cells. While these results further suggested
for augmenting and sustaining T cell responses via inter- a role for CTLA-4 in regulating peripheral T cell tolerance
action with CD28. However, the function of the B7 mole- in vivo, the mechanism by which CTLA-4 influences tol-
erance is unclear.
Here, we have demonstrated an essential role fork To whom correspondence should be addressed (e-mail: asharpe@
rics.bwh.harvard.edu). CTLA-4 in regulating the induction of anergy in vivo
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using naive TCR transgenic T cells lacking CTLA-4.
These studies overcome difficulties in interpreting re-
sults inherent in using anti-CTLA-4 mAbs and have al-
lowed for biochemical analyses of T cells given only an
antigenic stimulus. We adoptively transferred DO111
RAG22/2 or DO111 RAG22/2CTLA-42/2 T cells into synge-
neic wild-type (wt) recipients and compared the devel-
opment of the immune response to an immunogenic or
tolerogenic stimulus. In contrast to DO111 RAG22/2
cells, DO111 RAG22/2CTLA-42/2 T cells proliferate and
secrete IL-2 following a tolerogenic stimulus. Interest-
ingly, this tolerance resistance is not associated with a
defect in activation-induced cell death (AICD); however,
it is related to a role for CTLA-4 in regulating cell cycle
progression. Following encounter with a tolerogenic
stimulus in vivo and restimulation in vitro, DO111
RAG22/2 T cells arrest in the cell cycle at the early G1
phase. In contrast, DO111 RAG22/2CTLA-42/2 T cells
readily progress through G1 into the S phase of the cell
cycle. These findings demonstrate that CTLA-4 plays
an obligatory role in peripheral T cell tolerance by influ-
encing cell cycle progression and has significant impli-
cations for developing immune-based therapies geared
toward tolerance induction.
Results
T Cells in DO111 RAG22/2CTLA-42/2 Transgenic Mice
Are Naive
While the striking phenotype of the CTLA-42/2 mouse
strain demonstrates a key role for CTLA-4 in downregu-
lating T cell activation (Tivol et al., 1995), the rapid activa-
tion of the CTLA-42/2 T cells and the early demise of
these mice have made it difficult to use this strain to
study the function of CTLA-4 in the activation of naive
T cells. We initially bred the DO11 transgenic mice onto
the CTLA-42/2 background. DO11 mice express an MHC
class II–restricted transgenic TCR specific for (OVA)323–339 Figure 1. DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 T Cells
peptide (Murphy et al., 1990). At 6 to 8 weeks of age, Exhibit a Naive Phenotype and Respond Comparably to Antigen
DO111 CTLA-42/2 mice develop mild lymphadenopathy Lymph node cells were harvested from unstimulated DO111RAG22/2
and splenomegaly (Oosterwegel et al., 1999). This may and DO111 RAG22/2CTLA-42/2 mice, CD41 T cells were purified from
cell suspensions, and CD41 T cells were stained for the DO11.10result from the activation of T cells expressing hybrid
TCR with the clonotypic antibody KJ1-26 and CD4 and analyzed byTCRs or activation of DO111 T cells by cross-reactive
flow cytometry. The percentage of KJ1-261 CD41 T cells is indicatedligands. In order to generate T cells exclusively express-
on the FACS plot. Purified CD41 T cells were stained for CD4 and
ing the transgenic TCR, we have generated DO111 either CD25 or CD62L. The percentages of double-positive cells are
RAG22/2CTLA-42/2 mice that survive and show no signs indicated (1/1 and 2/2 denote CTLA-4 genotype). (B) CD41 T cells
of T cell activation, lymphadenopathy, or splenomegaly from DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 were cultured
with OVA323–339 and APCs for 4 days and restimulated for 3 days,for over 32 weeks. As shown in Figure 1A, T cells in both
then stained for KJ1-26, CD4, and CD25 or CD62L. The histogramDO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 mice are
plots represent cells gated on the KJ1-261 CD41 population (fillednaive, as demonstrated by similar levels of CD25 (IL-
histogram is CD25 or CD62L staining; dashed line is isotype-
2Ra) and CD62L (L-selectin) expression. In vitro activa- matched control). The results are representative of three experi-
tion with specific antigen increases CD25, CD62L, and ments with two to three mice per group.
CD28 expression comparably (Figure 1B; data not
shown), suggesting that the extent and kinetics of acti-
vation are similar. show comparable proliferation at day 4 (Figure 2A) and
a 1.7- to 2.4-fold increase in IL-2 production on days 2
and 3, respectively, during the primary response (FigureDO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 T Cells
Differ in Proliferation and Cytokine Production 2C). IFN-g and IL-4 production were not detected in
either group during the primary response (Figure 2C).during the Secondary Response
We initially compared immune responses of DO111 During the secondary response, proliferation of DO111
RAG22/2CTLA-42/2 T cells was 2.2- to 3.0-fold greater,RAG22/2 and DO111 RAG22/2CTLA-42/2 T cells to anti-
genic stimulation in vitro. During the primary response, as compared to DO111 RAG22/2 T cells at low doses
of peptide (Figure 2B). As shown in Figure 2C, DO111DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 T cells
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Figure 2. Levels of Proliferation and Effector
Cytokines Are Elevated during the Secondary
Responses of DO111 RAG22/2CTLA-42/2 T
Cells to Antigen Stimulation
(A–B) DO111 RAG22/2 (closed circles) (de-
noted as 1/1 to indicate CTLA-4 genotype)
or DO111 RAG22/2CTLA-42/2(open squares)
(denoted as 2/2 to indicate CTLA-4 geno-
type) T cells were purified and cultured with
mitomycin-C-treated APCs and OVA323–339 for 4
days. Proliferation was measured by 3[H]thymi-
dine incorporation during the primary re-
sponse at day 4 (A) and during the secondary
response at day 3 (B) at the indicated peptide
concentrations.
(C) Cytokine secretion was detected by ELISA
of culture supernatants in the primary at days
1–4 and in the secondary at days 1–3 after
stimulation with 1.0 mg/ml of OVA peptide.
Cells cultured in the absence of peptide did
not secrete measurable cytokines (data not
shown). The error bars represent standard
deviations. These results are representative
of three experiments.
RAG22/2 and DO111 RAG22/2CTLA-42/2 T cells produced shown in Figure 3, the percentage of apoptotic T cells
was comparable in DO111 RAG22/2 and DO111 RAG22/2similar levels of IL-2 on days 2 and 3 during the second-
ary response, but DO111 RAG22/2CTLA-42/2 T cells pro- CTLA-42/2 T cells. These results indicate that CTLA-4
does not play an obligatory role in AICD in previouslyduced higher levels of IFN-g and IL-4 than DO111
RAG22/2 T cells. Thus, DO111 RAG22/2CTLA-42/2 T cells activated T cells.
exhibit enhanced proliferation and cytokine production,
which is most pronounced upon restimulation with an- DO111 RAG22/2CTLA-42/2 T Cells Are Resistant to
Tolerance Induction In Vivotigen.
To directly evaluate the role of CTLA-4 in regulating the
response of naive T cells to an immunizing or tolerizingDO111 RAG22/2 and DO111 RAG22/2CTLA-42/2
T Cells Exhibit Similar Levels of stimulus in vivo, we used the well-established DO11
adoptive transfer model (Kearney et al., 1994). CD41Activation-Induced Cell Death
AICD occurs rapidly in primed T cells following restimu- T cells were purified from DO111 RAG22/2 or DO111
RAG22/2CTLA-42/2 mice and transferred into syngeneiclation with high doses of antigen or antibodies to CD3
(Van Parijs et al., 1996). One potential explanation for the wt recipients. One day later, recipients were either un-
treated (naive), immunized with OVA peptide in IFA sub-lymphoproliferative phenotype of the CTLA-42/2 mice is
that CTLA-42/2 T cells exhibit defects in AICD. To assess cutaneously (primed), or tolerized with a high dose of
OVA peptide in PBS intravenously (tolerized), as pre-the role of CTLA-4 in AICD, we activated purified DO111
RAG22/2 and DO111 RAG22/2CTLA-42/2 T cells with pep- viously described (Perez et al., 1997). The in vivo expan-
sion of DO111 T cells was measured by staining withtide and APCs for 4 days, rested the cells overnight in
IL-2, and then restimulated these T cells with varying the clonotypic antibody KJ1-26 on days 4 and 7 after
treatment (Figure 4). By days 4 and 7 following priming,concentrations of immobilized anti-CD3 in the presence
of IL-2. After 24 hr, cell death was assessed by double DO111 RAG22/2CTLA-42/2 T cells increased on average
2.2- and 1.4-fold more, respectively, than DO111staining for CD4 and propidium iodide incorporation. As
Immunity
148
Cell Cycle Progression Is Distinct in DO111 RAG22/2
and DO111 RAG22/2CTLA-42/2 T Cells Given
a Tolerogenic Stimulus
To further examine the role of CTLA-4 in T cell activation
and tolerance, we expanded our studies using the DO11
adoptive transfer model to compare cell cycle progres-
sion of T cells following an immunogenic or tolerogenic
stimulus. The in vivo expansion of DO111 T cells to a
tolerogenic stimulus, as shown by flow cytometry (Fig-
ure 4), suggested that the tolerized DO111 RAG22/2 T
cells undergo an initial expansion through the cell cycle.
To further evaluate cell cycling, we labeled DO111
RAG22/2 or DO111 RAG22/2CTLA-42/2 T cells with 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE)
prior to adoptive transfer. The wt recipients of the CFSE-
Figure 3. Activation-Induced Cell Death Is Comparable in DO111
labeled T cells were either untreated or given an immu-RAG22/2 and DO111 RAG22/2CTLA-42/2 T Cells
nogenic or tolerogenic stimulus. At day 3 after treatment,DO111 RAG22/2 (closed circles) or DO111 RAG22/2CTLA-42/2 (open
CD41 KJ1-261 T cells were analyzed by flow cytometrysquares) T cells were purified and cultured with mitomycin-C-treated
for CFSE expression (Figure 6). Levels of CFSE expres-APCs with OVA323–339 (1.0 mg/ml) for 4 days. T cells were rested
overnight with IL-2, and viable cells were cultured with IL-2 and sion are reduced in half each time a cell division occurs,
varying concentrations of plate-bound anti-CD3 (0–1.0 mg/ml). After and the pattern of fluorescence is detected by FACS.
24 hr, cell death was assessed by FACS analysis, which was indi- Strikingly, while tolerized DO111 RAG22/2 T cells un-
cated as propidium iodide incorporation by CD41 T cells. The error dergo a few rounds of cell division, DO111 RAG22/2
bars represent standard deviations for triplicate samples. The re-
CTLA-42/2 T cells continue to progress through the cellsults are representative of three experiments.
cycle and more closely resemble the primed groups.
Primed DO111 RAG22/2CTLA-42/2 T cells have lost the
majority of the CFSE label, indicating the highest degreeRAG22/2 T cells (Figure 4). DO111 RAG22/2CTLA-42/2 T
of cell cycling over 3 days. Primed DO111 RAG22/2 alsocells given a tolerogenic stimulus also expanded on
undergo numerous cell divisions but less than DO111average 2.2-fold greater on both days 4 and 7 than
RAG22/2CTLA-42/2 T cells. In addition, no cycling wasDO111 RAG22/2 T cells. The day 4 time point allowed
detected in untreated recipients, DO111 RAG22/2, orfor analysis of the tolerized T cells at the point of greatest
DO111 RAG22/2CTLA-42/2 T cells. Based on these find-expansion in vivo, while the day 7 time point reflects a
ings, the marked defect in the tolerized DO111 RAG22/2more stable population of tolerized T cells (Kearney et
T cells appears to occur in vivo and to manifest duringal., 1994). Although naive DO111 T cells were detected
reexposure to antigen. Thus, we examined the levels ofin untreated recipients, no expansion was observed in
cell cycle proteins following restimulation in vitro.
vivo.
The role of CD28 and CTLA-4 in regulating cell cycle
In vivo responses of wt and CTLA-42/2 T cells were
progression has been investigated in recent studies.
further evaluated by harvesting lymph nodes from recipi-
Stimulation through the B7:CD28 pathway promotes
ents and characterizing proliferation and IL-2 production progression through the G1 phase by downregulating
following restimulation with antigen in vitro. To measure levels of the cell cycle inhibitor p27kip1 and promoting
the proliferative capacity of the DO111 T cells, CD41 IL-2 gene transcription and protein secretion (Appleman
purified lymph node cells were cultured with wild-type et al., 2000). In contrast, in vitro cross-linking of CTLA-4
APCs and peptide for a period of 3 days. To more accu- engagement prevents the degradation of p27kip1 (Brun-
rately compare treatment groups, we normalized the ner et al., 1999), which may inhibit the transcription of
number of KJ1-261 CD41 T cells plated in order to adjust S phase genes. As shown in Figure 7A, naive T cells
for differences in cell expansion and recovery. Naive from untreated 6-week-old DO111 RAG22/2 and DO111
DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 T cells RAG22/2CTLA-42/2 mice have comparable high expres-
exhibit comparable proliferative responses at days 4 sion of p27kip1, modest levels of cdk4, and very low levels
and 7 upon restimulation in vitro (Figures 5A and 5B) of cdk2 protein expression.
and similar IL-2 production at day 4 (Figure 5A), but Since p27kip1 has been shown previously to have an
CTLA-42/2 T cells produce more IL-2 at day 7 (Figure active role in the induction of T cell anergy (Boussiotis
5B). Similarly, primed DO111 RAG22/2 and DO111 et al., 2000), we focused our studies on cell cyclins
RAG22/2CTLA-42/2 T cells exhibit strong proliferative re- associated with p27kip1 regulation. DO111 RAG22/2 and
sponses and secrete high levels of IL-2 at day 4 and DO111 RAG22/2CTLA-42/2 T cells were transferred into
day 7 after treatment. In contrast, DO111 RAG22/2 T wt recipients and left untreated (naive), primed, or toler-
cells that encountered a tolerogenic stimulus in vivo ized, and CD41 T cells were harvested from the adoptive
proliferated poorly and did not secrete IL-2 upon restim- transfer recipients for cell cycle analysis. Equal numbers
ulation in vitro. However, DO111 RAG22/2CTLA-42/2 T of KJ1-261 CD41 T cells were restimulated in vitro for
cells given a tolerogenic stimulus proliferated and se- 3 days with peptide and APCs, protein lysates were
creted IL-2 during restimulation. Taken together, these prepared, and the levels of protein were normalized. The
results demonstrate that T cells lacking CTLA-4 are re- expression of cyclin D2 and cdk4 was comparable in
sistant to tolerance induction, as demonstrated by their restimulated naive and tolerized DO111 RAG2/2 T cells
and similarly elevated in DO111 RAG2/2 primed androbust proliferation and IL-2 production.
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Figure 4. Expansion of DO111 RAG22/2CTLA-42/2 T Cells Is Greater Than DO111 RAG22/2 T Cells In Vivo
DO111 RAG22/2 were adoptively transferred into wt recipients and either untreated (naive), immunized subcutaneously with 50 mg OVA323–339
peptide in IFA (primed), or given 300 mg OVA323–339 in PBS intravenously (tolerized). At 4 and 7 days after treatment, draining lymph node cells
were harvested, cell suspensions pooled for each group, and CD41 T cells purified. A portion of the CD41 T cells were stained with KJ1-26
and CD4 to measure antigen-specific T cell expansion in vivo and analyzed by flow cytometry. One representative experiment of three, using
three to five mice per treatment group, is shown. The percentage of KJ1-261 CD41 T cells is indicated on the FACS plots. (Mean percent
expansion of KJ1-261 CD41 T cells in vivo. [Day 4] DO111 RAG22/2: naive 5 0.53 6 0.05, primed 5 6.2 6 1.2, and tolerized 5 3.9 6 0.92;
DO111 RAG22/2CTLA-42/2: naive 5 0.57 6 0.17, primed 5 14 6 5.1, and tolerized 5 8.6 6 0.57. [Day 7] DO111 RAG22/2: naive 5 0.38 6 0.13,
primed 5 9.0 6 0.81, and tolerized 5 1.1 6 0.36; DO111 RAG22/2CTLA-42/2: naive 5 0.55 6 0.05, primed 5 12.75 6 1.55, and tolerized 5
2.61 6 0.21.) The mean and standard deviations represent the average values for three experiments.
DO111 RAG2/2CTLA-42/2 naive, primed, and tolerized T naive treatment group and markedly elevated activity in
the primed group during in vitro restimulation (Figurecells (Figure 7B, panels 1 and 2). The expression of
cyclin D2 and cdk4 indicates that both DO111 RAG2/2 7B, panel 4, lanes 4 and 5).
We next examined whether the profound differenceand DO111 RAG2/2CTLA-42/2 primed and tolerized T
cells enter the G1 phase of the cell cycle after restimula- in cdk2 kinase activity between DO111 RAG22/2 and
DO111 RAG22/2CTLA-42/2 T cells might be due to alteredtion in vitro.
To determine the effect of CTLA-4 on progression expression of the cdk inhibitor p27kip1. The level of p27kip1
in DO111 RAG22/2 T cells was highest in tolerized Tthrough the late G1 phase and the G1 restriction point
into the S phase, cdk2 expression and kinase activity were cells, as compared to naive and primed T cells (Figure
7C, lanes 1–3). In contrast, in the DO111 RAG22/2examined. Cdk2 protein levels in restimulated cultures
of in vivo tolerized DO111 RAG22/2 T cells were reduced, CTLA42/2 T cells, expression of p27kip1 was lower in
primed and tolerized groups, as compared to the naiveas compared to restimulated naive and primed DO111
RAG22/2 T cells (Figure 7B, panel 3, lanes 1–3). In con- group (Figure 7C, lanes 4–6), indicating that the enzy-
matic activity of cdk2 was inversely correlated withtrast, in DO111 RAG22/2CTLA-42/2 T cells, cdk2 protein
expression was elevated in restimulated T cells from p27kip1 levels.
To distinguish whether CTLA-4 affects the cell cyclenaive, primed, and tolerized groups (Figure 7B, panel 3,
lanes 4–6). In DO111 RAG22/2 T cells, cdk2 kinase activ- in early G1 or at the G1 to S transition, we compared
Rb phosphorylation in wt and CTLA-42/2 T cells. In vivoity was highest in primed T cells and present in naive T
cells but minimal in tolerized T cells, only detectable activation of cdks results in phosphorylation of various
intracellular substrates, among which Rb protein is theafter prolonged exposure of the film (Figure 7B, panel
4, lanes 1–3; data not shown). Strikingly, DO111 most critical. Phosphorylation of Rb prevents binding
to E2F-type transcription factors, thus allowing for theRAG22/2CTLA-42/2 T cells given a tolerogenic stimulus
had markedly increased cdk2 kinase activity, as com- initiation of transcription of S phase genes (Appleman
et al., 2000). Therefore, the presence of hyperphosphor-pared to the naive treatment group, reflecting that these
cells were progressing through the cell cycle and primed ylated Rb is an indicator of cell cycle progression into
the S phase. We examined the phosphorylation statusin vivo (Figure 7B, panel 4, lane 6). There was also moder-
ately increased cdk2 enzymatic activity in the CTLA-42/2 of endogenous Rb from DO111 RAG2/2 and DO111
Immunity
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Figure 5. DO111 RAG22/2CTLA-42/2 T Cells
Are Resistant to Tolerance Induction In Vivo
DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2
were adoptively transferred and treated (na-
ive, primed, and tolerized) 1 day later. Lymph
nodes were harvested at days 4 and 7 after
treatment. KJ1-261 CD41 T cells were cul-
tured with wild-type mitomycin-C-treated
APCs and OVA323–339 peptide. Proliferation
was measured at day 3 of restimulation for
DO111 RAG22/2 (closed circles) or DO111
RAG22/2CTLA-42/2 (open squares) over a
range of peptide doses (0–1.0 mg/ml). IL-2
production was detected from culture super-
natants on days 1–3 for each treatment group
restimulated with 1.0 mg/ml of peptide. Each
time point reflects the mean of triplicate sam-
ples, and error bars represent standard devi-
ations. One representative experiment of
three, using three to five mice per treatment
group, is shown.
RAG22/2CTLA-42/2 T cells isolated from naive, primed, groups, indicating the cells were progressing through
the cell cycle, consistent with the absence of toleranceand tolerized recipient mice after 3 days of in vitro re-
stimulation. As shown in Figure 7D, in naive and primed induction in cells lacking CTLA-4. When DO111 and non-
DO11 cells were separated at day 3 following in vitroDO111 RAG22/2 T cells, a significant proportion of Rb
protein is in the hyperphosphoryated form, which has restimulation using magnetic beads, the Rb hyper-
phosphorylation was observed only in the DO111 T cella slower electrophoretic mobility (upper band) (Figure
7D, lanes 2 and 3), whereas in the tolerized DO111 fraction, discounting the possibility of bystander effects
by non-DO11 recipient cells (data not shown). Our re-RAG22/2 T cells the hypophosphorylated form (lower
band) predominates (Figure 7D, lane 4), which is a hall- sults demonstrate that antigen-specific T cells tolerized
in vivo enter the G1 phase of the cell cycle but aremark of the early G1 phase. In contrast, in the DO111
RAG22/2CTLA-42/2 T cells, hyperphosphorylation of Rb blocked in the early G1 phase and are unable to progress
into the S phase. Strikingly, CTLA-42/2 T cells do notwas observed in T cells in naive, primed, or tolerized
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induced cell death. Although one report suggested that
cross-linking of CTLA-4 on activated CD41 T cells leads
to apoptosis in a significant fraction of the T cells
(Scheipers and Reiser, 1998a), other reports have shown
that engagement of CTLA-4 leads to cell cycle arrest
without apoptosis and allows for induction of bcl-xL
(Krummel and Allison, 1996; Walunas et al., 1996; Blair
et al., 1998; Khattri et al., 1999). Our findings demon-
strate that CTLA-4 is not essential for AICD.
Since our studies did not indicate that CTLA-4 regu-
lates peripheral T cell tolerance by altering AICD, we
focused on the role of CTLA-4 in the regulation of cell
cycle progression. Engagement of CTLA-4 by cross-
linking or by B7 binding has been shown to prevent cell
cycle entry at the G1 phase and subsequently to inhibit
IL-2R expression and IL-2 production (Krummel and Alli-
son, 1996). A later study has shown that CTLA-4 engage-
ment in vitro prevents the degradation of p27kip1(Brunner
et al., 1999). We extended these studies by analyzing
the levels of cell cycle proteins at regulatory checkpoints
throughout the G1 and S phase of the cell cycle in T
cells given an immunogenic or tolerogenic stimulus in
vivo. Interestingly, both DO111 RAG22/2 and DO111
RAG22/2CTLA-42/2 T cells given a tolerogenic stimulus
are able to enter the G1 phase, as demonstrated by
expression of cyclin D and cdk4. However, striking rela-
tive differences in cdk2 protein expression and kinase
activity were observed between DO111 RAG22/2 and
DO111 RAG22/2CTLA-42/2 T cells given a tolerogenic
stimulus, demonstrating that CTLA-4 affects cell cycle
progression at the G1 to S transition. While DO111
RAG22/2 tolerized T cells expressed cdk2 protein, cdk2Figure 6. Cell Cycling Is Greater in DO111 RAG22/2CTLA-42/2 T Cells
Given a Tolerogenic Stimulus In Vivo kinase activity was markedly reduced as compared to
Division of CFSE-labeled DO111 RAG22/2 (solid line) or DO111 DO111 RAG22/2CTLA-42/2 T cells given a tolerogenic
RAG22/2CTLA-42/2 (dashed line) T cells after adoptive transfer into stimulus, indicating that DO111 RAG22/2 T cells were
wt recipients. At day 3 following treatment (naive, primed, or toler- prevented from progressing through the cell cycle dur-
ized), draining lymph nodes were collected. Cell suspensions were ing in vitro restimulation. Our results are consistent with
stained for CD4 and KJ1-26. Histograms represent CFSE expression
in vitro anergy studies in which tolerized T cells aregated on CD41 KJ1-261 T cells. These results are representative of
blocked at the G1 phase (Gilbert et al., 1992; Gilbert andthree experiments.
Weigle, 1993; Powell et al., 1999; Boussiotis et al., 2000;
Frauwirth et al., 2000). In our system, levels of the cell
cycle inhibitor p27kip1 were higher in tolerized DO111exhibit this blockade upon being exposed to a tolerogenic
RAG22/2 T cells as compared to similarly treated DO111stimulus and readily enter the S phase of the cell cycle.
RAG22/2CTLA-42/2 T cells. Moreover, levels of phos-
phorylated Rb were markedly increased in DO111
Discussion RAG22/2CTLA-42/2 T cells in the tolerized treatment
group as compared to DO111 RAG22/2 T cells. Thus,
In this study, we have investigated the role of CTLA-4 tolerized DO111 RAG22/2 T cells enter the G1 phase of
in the development of peripheral T cell tolerance in vivo the cell cycle; however, they are prevented from pro-
using the DO11 adoptive transfer model. DO111 RAG22/2 ceeding into the S phase, in contrast to DO111
CTLA-42/2 T cells given a tolerogenic stimulus exhibit a RAG22/2CTLA-42/2 T cells. Our findings are novel in dem-
vigorous immune response, characterized by marked onstrating that the presence of CTLA-4 is obligatory for
proliferation, progression through the cell cycle, and IL-2 the induction of the G1 cell cycle arrest in tolerized T
production, while similarly treated DO111 RAG22/2 T cells, since CTLA-42/2 T cells can progress through the
cells proliferate poorly and do not secrete IL-2. Our cell cycle. Differences in cell cycle progression in
studies build on those of Perez et al. and demonstrate CTLA-42/2 T cells may explain why DO111 RAG22/2
an obligatory role for CTLA-4 in tolerance induction CTLA-42/2 T cells are resistant to tolerance induction by
(Perez et al., 1997; Van Parijs et al., 1997). The DO111 antigen, whereas DO111 RAG22/2 T cells are suscepti-
RAG22/2CTLA-42/2 mouse strain was required for these ble. Using a complementary approach, we have com-
studies, given the early activation of CTLA-42/2 T cells pared B7-1/B7-22/2 and B7-1/B7-2/CTLA-42/2 T cells
and the lethal autoimmune phenotype of the CTLA-42/2 and found that CTLA-4 regulates the kinetics and ex-
strain. pression of cell cycle proteins during priming, indicating
We examined the possibility that CTLA-4 influences a fundamental difference in cell cycle progression in T
cells lacking CTLA-4 (our unpublished data).peripheral T cell tolerance by regulating activation-
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For example, the threshold for T cell activation may
be lowered in the CTLA-42/2 T cells so that increased
signaling through CD28 can convert a tolerogenic stimu-
lus into being immunogenic. Further studies are needed
to determine the molecular mechanism by which CTLA-4
influences T cell tolerance. CTLA-4 may directly influ-
ence TCR-mediated signals. Studies of CTLA-4 signal-
ing have indicated that following T cell activation CTLA-4
may block tyrosine phosphorylation by directly inter-
acting with the TCR complex z chain (Lee et al., 1998).
B7-1:CTLA-4 interactions also have been linked with
antagonism of TCR-mediated signals in a CD28-inde-
pendent system (Fallarino et al., 1998).
Other studies have suggested that CTLA-4 may alter
T cell function by regulating the production of soluble
immunoregulatory cytokines, such as transforming growth
factor b production (TGF-b), suggesting a potential regu-
latory mechanism by which it exerts its inhibitory effects
(Chen et al., 1998). Both TGF-b and CTLA-4 downregu-
late immune responses, and the phenotype of the TGF-
b2/2 and CTLA-42/2 mouse strains are similar. Further
support for a role for CTLA-4 in controlling production
of soluble regulatory molecules comes from a recent
study that suggested that the defect in CTLA-42/2 mice
was not cell autonomous (Bachmann et al., 1999). Re-
constitution of RAG22/2 mice with a mixture of wt and
CTLA-42/2 bone marrow did not result in disease,
whereas RAG22/2 recipients of CTLA-42/2 bone marrow
developed lymphocyte infiltration primarily into the peri-
cardium and liver but not the lymphoproliferative disor-
der observed in CTLA-42/2 animals (Bachmann et al.,
1999). These findings suggest that factors produced
by wt T cells can block the development of CTLA-42/2
disease; however, this study did not support a role for
TGF-b. In our experiments, CTLA-42/2 T cells manifest
a resistance to anergy even in the presence of a great
excess of wild-type cells in the transfer recipients, sug-
gesting that the CTLA-4 defect is cell intrinsic.
In contrast to our findings, T cells from 2C RAG22/2
CTLA-42/2 mice were shown to be tolerized in vitro
Figure 7. DO111 RAG22/2 but Not DO111 RAG22/2CTLA-42/2 T Cells
(Frauwirth et al., 2000). Several potential differences inGiven a Tolerogenic Stimulus Are Arrested at the G1 Phase of the
our model systems may explain these opposing results.Cell Cycle
First, the method of inducing tolerance is very different.(A) Lysates from unstimulated DO111 RAG22/2 and DO111
In our system, antigen-specific T cells are tolerized withRAG22/2CTLA-42/2 T cells were analyzed by SDS-PAGE and immu-
noblotted with antiserum specific for p27kip1. Blots were stripped a high dose of soluble antigen without adjuvants in vivo,
and reprobed with antiserum specific for cdk4 and cdk2. and CTLA-42/2 T cells encounter local APCs expressing
(B) Following adoptive transfer of DO111 RAG22/2 and DO111 low levels of B7 and processed antigen within an in vivo
RAG22/2CTLA-42/2 T cells and treatment (N, naive; P, primed; or T, microenvironment. In contrast, 2C TCR Tg T cells were
tolerized), CD41 KJ1-261 T cells were restimulated with mitomycin-
stimulated with anti-CD3 in an in vitro system prior toC-treated APCs and OVA peptide for 3 days. At day 3, lysates were
restimulation with specific peptide. In this in vitro sys-prepared and analyzed by SDS-PAGE and immunoblotted with anti-
tem, the effects of CTLA-4 during the induction phaseserum specific for cyclin D2, cdk4, or cdk2. To assay kinase activity,
immunoprecipitations were performed with anti-cdk2-specific anti- of tolerance may be masked by using a potent TCR
serum, and in vitro kinase reactions were done using histone H1 as stimulus or may even induce AICD. Second, the require-
exogenous substrate. ment for CTLA-4 in tolerance induction may be different
(C) The same immunoblots used in (B) were stripped and reprobed for CD41 (DO11 TCR) versus CD81 (2C TCR) T cells.
with monoclonal antibody specific for p27kip1.
While some recent reports indicate a role for CTLA-4 in(D) Lysates from the same samples described above (“unst,” unstim-
mediating tolerance induction in CD81 T cells in a tumorulated), were immunoblotted with monoclonal antibody specific for
model (Deeths et al., 1999; Shrikant et al., 1999), otherRb. Densitometric values are provided on each blot. Results are
representative of three experiments. systems do not support these findings (Sotomayor et
al., 1999).
Previous studies had suggested a role for CTLA-4
Another, although not mutually exclusive, mechanism in regulating Th2 differentiation; however, our findings
why CTLA-42/2 T cells are resistant to tolerance induc- indicate that both Th1 and Th2 cytokines are increased
in CTLA-42/2 T cells (Oosterwegel et al., 1999; Kato andtion may be related to unopposed B7:CD28 interactions.
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purified from pooled lymph nodes using anti-CD4 (L3T4) DynabeadsNariuchi, 2000). By restricting the TCR to expression of
and Detachabeads (Dynal, Oslo, Norway). Purity of the populationsonly the DO11 transgene, the DO111 RAG22/2CTLA-42/2
was assessed by double staining with CD4-PE (PharMingen) andT cells exhibit a naive phenotype. During the primary
KJ1-26-FITC (Caltag) and analyzed by flow cytometry. Cells were
response, DO111 RAG22/2CTLA-42/2 T cells exhibited washed with RPMI plating media (GIBCO–BRL, Grand Island, NY)
increases in IL-2, but effector cytokines were not de- supplemented with 10% fetal bovine serum (Sigma), 2 mM L-gluta-
mine (GIBCO–BRL), 1X antibiotic-anti-mycotic (GIBCO–BRL), 0.01 Mtected. Previously, both IL-2 and IL-4 were detected in
HEPES buffer (GIBCO–BRL), 10 mg/ml gentamicin (GIBCO–BRL),the primary response using DO111 CTLA-42/2 T cells
and 6 3 1025 M B-mercaptoethanol (Sigma). During the primary(Oosterwegel et al., 1999). Although DO111 CTLA-42/2
response, 2 3 105 CD41 KJ1-261 T cells were cultured in 24-wellmice do not develop CTLA-42/2 disease early, mild sple-
plates for 4 days with 2 3 106 mitomycin-C-treated (Sigma) APCs
nomegaly and lymphadenopathy resulted from the acti- and 0–1.0 mg/ml OVA323–339 peptide. At day 4, T cells primed with
vation of both endogenous and transgenic T cells by OVA peptide (1.0 mg/ml) were rested overnight with 50 U/ml of IL-2,
then restimulated in vitro under the same conditions as in the primary6–8 weeks. It is likely that DO111 CTLA-42/2 T cells are
response. To measure proliferation, 2 3 104 T cells and 2 3 105activated or exposed to activated non-TCR transgenic
APCs were cultured in 96-well plates, pulsed with 1 mCi of 3[H]thymi-T cells in vivo. Even though naive CD62L1 T cells were
dine (New England Nuclear) on day 4 (primary response) and day 3sorted in our previous studies, this approach may not
(secondary response) for 6 hr and then harvested for liquid scintilla-
have excluded the possibility of skewing to the Th2 tion counting (Wallac, Gaithersburg, MD). Data reflect the mean of
phenotype during priming and/or as a result of being in triplicates from each peptide concentration. Culture supernatants
were collected on each day of primary and secondary responsean environment with activated T cells. Consequently,
from T cell cultures with 0 or 1.0 mg/ml of OVA323–339. Cytokine levelsincreased Th2 cytokines were observed during the sec-
were determined by ELISA as described previously (Schweitzer etondary responses. On the RAG22/2 background, prior
al., 1997) and reflect values from triplicate wells.activation of the CTLA-42/2 T cells is minimized, and
during antigen restimulation both Th1 and Th2 effector In Vitro Cell Death Assays
cells are observed. These findings are consistent with To examine the level of AICD, 2 3 105 DO111 RAG22/2 or DO111
the CTLA-42/2 disease phenotype, which exhibits in- RAG22/2CTLA-42/2 T cells were activated in vitro for 4 days with 1.0
mg/ml of OVA323–339 and 2 3 106 mitomycin C–treated APCs. On daycreased Th1 and Th2 cytokines (Tivol et al., 1995).
4, the cells were collected and cultured overnight in medium con-Our results demonstrate that CTLA-42/2 T cells are
taining 50 U/ml of IL-2 (PharMingen). To assay AICD, T cells wereresistant to tolerance induction in vivo and exhibit a
cultured for 24 hr in the absence or presence of plate-bound anti-
fundamental alteration in cell cycle progression as com- CD3 (0–1.0 mg/ml) (Bioexpress, New Lebanon, NH) and 50 U/ml of
pared to wt T cells. Regulation of the cell cycle by IL-2. The cells were stained with CD4-FITC (PharMingen), fixed in
CTLA-4 may provide an explanation for enhanced T cell a 70% ethanol solution, and apoptosis was assessed by propidium
iodide incorporation (Sigma).responses in disease models. For instance, CTLA-4
blockade has been shown to exacerbate autoimmune
Adoptive Transfers and Immunizationsdisease (Karandikar et al., 1996; Perrin et al., 1996;
For T cell transfers, DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2Luhder et al., 1998) and augment antitumor responses
lymph node and spleen cells were collected and cell suspensions
(Leach et al., 1996). In summary, our studies demon- were pooled and washed through a 70 mM filter. Cells were washed
strate that CTLA-4 has a pivotal role in determining T with RPMI plating media as described above. CD41 T cells were
cell activation versus tolerance. purified by positive selection using CD4 (L3T4) Dynal beads. Prior
to adoptive transfer, an aliquot of purified CD41 T cells was double
Experimental Procedures stained for FACS analysis with CD4-PE and KJ1-26-FITC. KJ1-261
CD41 cells (3.0 3 106)were adoptively transferred intravenously into
nonirradiated, syngeneic BALB/c wild-type recipients. At day 1 afterMice
BALB/c mice, 6 to 8 weeks old, were purchased from Taconic Labo- cell transfer, mice were either untreated (naive group), immunized
subcutaneously with 50 mg of OVA 323–339 peptide emulsified in incom-ratory (Germantown, NY) and used as syngeneic recipients. BALB/c
DO11.10 TCR transgenic mice were bred onto the CTLA-42/2 back- plete Freund’s adjuvant (Difco, Detroit, MI) (primed group), or toler-
ized with 300 mg of OVA 323–339 peptide in PBS intravenously (tolerizedground as described recently (Oosterwegel et al., 1999). BALB/c
RAG22/2 mice were a generous gift from Dr. Donald Mosier (Scripps group). Four or seven days later, cells were harvested from inguinal
and popliteal draining lymph nodes.Research Institute, La Jolla, CA) and intercrossed with DO111 or
DO111 CTLA-41/2 mice to produce homozygous mutants. Mice were
maintained in our breeding colony and cared for in accordance with CFSE Labeling
the institutional guidelines of Brigham and Women’s Hospital and To label the CD41 T cells with the fluoresecent dye CFSE (Molecular
Harvard Medical School. Probes, Eugene, OR) prior to adoptive transfer, the CFSE was diluted
to a final concentration of 1 mM. Purified DO111 RAG22/2 and DO111
RAG22/2CTLA-42/2 T cells at a concentration of 107/ml and CFSEFlow Cytometry
The activation status of the DO111 RAG22/2 and DO111 RAG22/2 were incubated at 378C for 12 min in nonsupplemented RPMI
(GIBCO–BRL). The labeled cells were washed once with equal vol-CTLA-42/2 mice was assessed by triple staining lymph node cells
with KJ1-26-FITC (Caltag, Burlingame, CA) to identify DO111 T cells, umes of 100% fetal bovine serum (Sigma), washed three times with
sterile PBS, and set to a final concentration of 3 3 106/200 ml perCD4-CyC (PharMingen, San Diego, CA), and CD25-PE (PharMingen),
CD62L-PE (PharMingen), or control rat IgG2a. The cells were injection prior to adoptive transfer. At day 1 after transfer, the recipi-
ents were left untreated or given an immunogenic or tolerogenicwashed with PBS with 1% bovine serum albumin (Sigma, St. Louis,
MO) and 0.01% sodium azide (Sigma) and analyzed on a Becton stimulus as described above. After 3 days, recipients were sacrificed
and inguinal and popliteal lymph nodes were collected. Cell suspen-Dickinson FACSCalibur machine and Cell Quest software. The per-
centage of DO111 T cells was determined prior to adoptive transfer sions were stained with KJ1-26-PE (Caltag) and CD4-cyc (Phar-
Mingen). CFSE staining was detected by flow cytometry, and CFSEand after treatment by double staining with KJ1-26-FITC and CD4-
PE (PharMingen). analysis was done on KJ1-261 CD41 T cells.
Restimulation Assays from In Vivo ExperimentsIn Vitro Cell Preparations
To compare the primary and secondary responses of DO111 To assess T cell priming in vivo, lymph node cells were harvested
from naive, primed, or tolerized recipients and restimulated withRAG22/2 or DO111 RAG22/2CTLA-42/2 T cells, CD41 T cells were
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OVA323–339 peptide in vitro. Lymph nodes were collected from three Bachmann, M.F., Kohler, G., Ecabert, B., Mak, T.W., and Kopf, M.
(1999). Cutting edge: lymphoproliferative disease in the absence ofto five mice per group and pooled prior to CD41 T cell purification
with anti-CD4 Dynal beads. Proliferative responses were measured CTLA-4 is not T cell autonomous. J. Immunol. 163, 1128–1131.
by culturing 1 3 104 KJ1-261 T cells with 2.0 3 105 mitomycin-C- Blair, P.J., Riley, J.L., Levine, B.L., Lee, K.P., Craighead, N., Fran-
treated, CD4- and CD8-depleted APCs (ATCC, Rockville, MD) with comano, T., Perfetto, S.J., Gray, G.S., Carreno, B.M., and June, C.H.
0–1.0 mg/ml OVA323–339 peptide for 72 hr in RPMI plating media as (1998). CTLA-4 ligation delivers a unique signal to resting human
previously described (Schweitzer et al., 1997). The number of KJ1- CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L)
261 T cells for each group of recipients was determined by FACS induction. J. Immunol. 160, 12–15.
analysis, and proliferation was normalized for KJ1-26 input. To mea-
Boussiotis, V.A., Freeman, G.J., Taylor, P.A., Berezovskaya, A.,
sure proliferation, cells were pulsed with 1 mCi of 3[H]thymidine on
Grass, I., Blazar, B.R., and Nadler, L.M. (2000). p27kip1 functions
day 3 for 6 hr and then harvested for liquid scintillation counting.
as an anergy factor inhibiting interleukin 2 transcription and clonal
Data reflect the mean of triplicates from each peptide concentration.
expansion of alloreactive human and mouse helper T lymphocytes.
Supernatants were collected from 24-well plates in which 1.0 3 105
Nat. Med. 6, 290–297.
antigen-specific T cells and 2.0 3 106 APCs were stimulated with
Brunner, M.C., Chambers, C.A., Chan, F.K., Hanke, J., Winoto, A.,either 0 or 1.0 mg/ml of OVA 323–339 peptide. Culture supernatants
and Allison, J.P. (1999). CTLA-4-mediated inhibition of early eventswere collected on days 1–3, and cytokine levels were determined
of T cell proliferation. J. Immunol. 162, 5813–5820.by ELISA.
Chai, J.G., and Lechler, R.I. (1997). Immobilized anti-CD3 mAb in-
duces anergy in murine naive and memory CD41 T cells in vitro.Immunoblotting, Immunoprecipitation, and In Vitro
Int. Immunol. 9, 935–944.Kinase Assays
Following the indicated adoptive transfer and restimulation condi- Chen, W., Jin, W., and Wahl, S.M. (1998). Engagement of cytotoxic
tions, cell lysates were prepared on day 3 of in vitro restimulation T lymphocyte-associated antigen 4 (CTLA-4) induces transforming
and equal amounts of protein (50 mg/sample) analyzed by 10% SDS- growth factor beta (TGF-beta) production by murine CD4(1) T cells.
PAGE, transferred onto nitrocellulose membranes, and immunoblot- J. Exp. Med. 188, 1849–1857.
ted with the indicated mAbs or antiserum. To determine levels of Deeths, M.J., Kedl, R.M., and Mescher, M.F. (1999). CD81 T cells
cell cycle proteins in unstimulated T cells, T cells were purified from become nonresponsive (anergic) following activation in the pres-
DO111 RAG22/2 and DO111 RAG22/2CTLA-42/2 mice, and cell lysates ence of costimulation. J. Immunol. 163, 102–110.
were prepared. Cyclin D2, cdk4, and cdk2 antiserum was purchased
Fallarino, F., Fields, P.E., and Gajewski, T.F. (1998). B7-1 engage-from Santa Cruz Biotechnology (Santa Cruz, CA) and p27kip1 mAb
ment of cytotoxic T lymphocyte antigen 4 inhibits T cell activationfrom Signal Transduction laboratories (Lexington, KY). To determine
in the absence of CD28. J. Exp. Med. 188, 205–210.the phosphorylation status of Rb, proteins were analyzed by 6%
Frauwirth, K.A., Alegre, M.L., and Thompson, C.B. (2000). InductionSDS-PAGE, transferred onto nitrocellulose membrane, and immu-
of T cell anergy in the absence of CTLA-4/B7 interaction. J. Immunol.noblotted with Rb-specific mAb (PharMingen). After immunoblotting
164, 2987–2993.with mAbs or antiserum, immunodetection was performed by incu-
bation with HRP-conjugated anti-mouse IgG (1:5000) or HRP-conju- Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo, V.,
gated anti-rabbit IgG (1:10,000) (Promega, Madison, WI) and devel- Lombard, L., Gray, G.S., and Nadler, L.M. (1993). Cloning of B7-2:
oped by chemiluminescence (NEN, Boston, MA). a CTLA-4 counter-receptor that costimulates human T cell prolifera-
For in vitro kinase reactions, immunoprecipitations were per- tion. Science 262, 909–911.
formed using equal amounts of protein (500 mg/sample) with anti- Gilbert, K.M., and Weigle, W.O. (1993). Th1 cell anergy and blockade
cdk2-specific antiserum agarose conjugate (Santa Cruz Biotechnol- in G1a phase of the cell cycle. J. Immunol. 151, 1245–1254.
ogy), and in vitro kinase reactions were done using histone H1
Gilbert, K.M., Ernst, D.N., Hobbs, M.V., and Weigle, W.O. (1992).
(Sigma) as an exogenous substrate, according to a previously de-
Effects of tolerance induction on early cell cycle progression by Th1
scribed protocol (Matsushime et al., 1994). Reactions were analyzed
clones. Cell. Immunol. 141, 362–372.
by 10% SDS-PAGE, transferred to a PVDF membrane, and exposed
June, C.H., Bluestone, J.A., Nadler, L.M., and Thompson, C.B.to X-ray film. Densitometric analyses were determined as previously
(1994). The B7 and CD28 receptor families. Immunol. Today. 15,described (Appleman et al., 2000).
321–331.
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